2018

Influence of Depression on Treatment and Survival: A Population-based Study in Patients with Breast Cancer in Kentucky

Feitong Lei
University of Kentucky, feitonglei0504@uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
https://uknowledge.uky.edu/cph_etds/220

This Graduate Capstone Project is brought to you for free and open access by the College of Public Health at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.) by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@hs.uky.edu.
STUDENT AGREEMENT:

I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine).

I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.

I retain all other ownership rights to the copyright of my work. I also retain the right to use in future works (such as articles or books) all or part of my work. I understand that I am free to register the copyright to my work.

REVIEW, APPROVAL AND ACCEPTANCE

The document mentioned above has been reviewed and accepted by the student’s advisor, on behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of the program; we verify that this is the final, approved version of the student’s dissertation including all changes required by the advisory committee. The undersigned agree to abide by the statements above.

Feitong Lei, Student

Dr. Bin Huang, Major Professor

Dr. Sarah Wackerbarth, Director of Graduate Studies
Influence of Depression on Treatment and Survival: A Population-based Study in Patients with Breast Cancer in Kentucky
Contents

NOTES ........................................................................................................................................ 1

Breast Cancer and Depression among Breast Cancer Survivors ............................................... 1
Previous Studies about Depression on Survival and Treatment Among Breast Cancer Patients ....... 2
Initial Analysis Plan ....................................................................................................................... 8
Selection Criterion ........................................................................................................................ 9
Breast Cancer Guideline Treatment Algorithm .......................................................................... 15
References .................................................................................................................................. 17

SAS CODES ................................................................................................................................. 18

Creating Formats for Categorical Variables ............................................................................... 18
Format Assignment ...................................................................................................................... 21
Merging Census Tract Related Information with Primary Data .................................................. 22
Data Cleaning and Data Management ....................................................................................... 23
Comparison between Patients Group Based on Depression Status .......................................... 29
Logistic Regression and Cox Regression .................................................................................... 31

OUTPUTS ..................................................................................................................................... 33

Table 1. Patients Characteristics (n=6054) ............................................................................... 33
Table 2. Standard Treatment (n=5559) ..................................................................................... 35
Table 3. Multivariable logistic regression to identify the association between depression status and nonguideline cancer treatment ........................................................................ 37
Figure 1. Survival curves in breast cancer patients grouped based on depression ................... 38
Figure 2. Survival curves in breast cancer patients grouped based on Appalachian Status ......... 39
Tables 4. Adjusted Cox hazard regression to identify the association between depression and survival. .................................................................................................................................. 40
Tables 4. Adjusted Cox hazard regression to identify the association between depression and survival (Cont.) ........................................................................................................... 41

RESULTS ..................................................................................................................................... 42
LESSONS LEARNED ............................................................................................................. 43

FINAL PAPER..................................................................................................................... 44
Breast Cancer and Depression among Breast Cancer Survivors

Breast cancer starts when cells in the breast begin to grow out of control. These cells usually form a tumor that can often be seen on an x-ray or felt as a lump. The tumor is malignant (cancer) if the cells can grow into (invade) surrounding tissues or spread (metastasize) to distant areas of the body. Risk factors for developing breast cancer include being female, obesity, lack of physical exercise, drinking alcohol, hormone replacement therapy during menopause, ionizing radiation, early age at first menstruation, having children late or not at all, older age, prior history of breast cancer, and family history. Except for skin cancer, breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer mortality in women. Currently, more than three million women are living with breast cancer in the United States. Previous studies have illustrated breast cancer survival is determined by factors including age, ethnicity, comorbidity, socio-economic factors, stage of cancer at diagnosis, and treatment.

Depression (major depressive disorder or clinical depression) is a common but serious mood disorder. It causes severe symptoms that affect how you feel, think, and handle daily activities, such as sleeping, eating, or working. To be diagnosed with depression, the symptoms must be present for at least two weeks. In fact, cancer and treatment-related symptoms can be major stressors in a patient with breast cancer who is undergoing treatment for the disease. Therefore, addressing the impact of breast cancer and its treatment on long-term outcomes is an important issue. Depression is a noticeably common mental health outcome among breast cancer survivors, and its hypothesized association with adverse survival in breast cancer patients has been of interest in the past decade. Studies estimated that about 10% to 25% of breast cancer patients experience depression, which is higher compared with matched control group.
Previous Studies about Depression on Survival and Treatment Among Breast Cancer Patients

1. **Survival after Early-stage breast cancer of women previously treated for depression: A nationwide Danish cohort study.**

- **Year:** 2017
- **Journal:** Journal of Clinical Oncology
- **Sample Population:** 45,325 women with early breast cancer in Denmark from 1998 to 2011 (744 women had a previous hospital contact, 6068 treated with antidepressants.
- **Conclusion:** Women previously treated for depression constitute a large subgroup of patients with breast cancer who are at risk for receiving nonguideline breast cancer treatment. Which probably contributes to poorer overall and breast cancer-specific survival.
- **Depression Identification:** 1. To capture the most severe) # hospital months before diagnosis of cancer (ICD-8); 2. Treatment with depressants form 3 months before diagnosis of breast cancer and 3 years previously (Prescription Registry).
- **Results:** 1. Those with previous hospital contact for depression or who dad used antidepressants were likely to be older, have less education, live alone, have comorbid somatic disease, and have breast cancer in later calendar year. 2. More women who had antidepressants received only a biopsy and not surgery and were therefore more likely to have unknown tumor size, number of tumor -positive lymph nodes, and ER status. 3.Statistically significantly fewer women who had used antidepressants were allocated to guideline systemic adjuvant therapy. 4. 80% previously treated for depression still use antidepressants after cancer diagnosis. 23% who not, started to use after diagnosis of breast cancer. 5. Women who had used antidepressants were not allocated to guideline breast cancer treatment (p<0.05, OR=1.14). Previously hospital contact (OR=1.32, 95%CI (0.99,1.77)). 6. There's no difference in term of survival among patients with and without depression, if they all received adjuvant treatment according to the guidelines.
- **Limitation:** 1. Other conditions such as anxiety and pain might account for more than 25 % of prescribed antidepressants. 2. Possible misclassification of breast cancer specific death.

- Year: 2016
- Journal: Psychology
- Sample Population: 77173 patients diagnosed with breast cancer in South East England from 2000 to 2009 (depression = 955). Of these patients, 422 had a prior record of a diagnosis of depression, and 533 had a new record of depression after the cancer diagnosis.
- Conclusion: There is evidence that English breast cancer patients with depression and bipolar recorded in routine hospital data have worse overall survival than those without these mood disorders.
- Depression Identification: Patients with a diagnosis of at least one depressive episode (ICD - 10 F32) and recurrent depressive disorder (ICD - 10 F33) where these were recorded within HES in the 3 years before and the year following the cancer diagnosis. Patients with a diagnosis of either a recurrent depressive disorder or a depressive episode were grouped together as ‘depression’, either a recurrent depressive disorder or a depressive episode were grouped together as ‘depression’.
- Results: 1. A record of depression was a predictor of worse overall survival in breast cancer patients (adjusted HR = 1.33, 95% CI: 1.20–1.48, p < 0.001), while the effect of bipolar was not statistically significant (adjusted HR = 1.33, 95% CI: 0.97–1.82, p = 0.079). New recordings of depression and bipolar diagnoses following a cancer diagnosis appeared better predictors of overall survival than a prior history of either. 2. Patients with a record of depression before or following the breast cancer diagnosis had a higher risk of dying even after adjusting for age, ethnicity, deprivation, comorbidities, stage of disease and treatment (fully adjusted HR = 1.33, 95% confidence interval (CI): 1.20–1.48, p < 0.001). The timing of the onset of depression appeared to be important. Depression recorded prior to the cancer diagnosis had a high unadjusted hazard ratio of 2.29 (95% CI: 1.98–2.64, p < 0.001) (Table 2), but this reduced to 1.23 (95% CI: 1.07–1.42, p = 0.005) after adjustment, with the main attenuating factors being age, comorbidity and stage. Depression after the cancer diagnosis, when no previous history of depression had been recorded, demonstrated a high hazard ratio of 1.69 (95% CI: 1.46–1.95, p < 0.001) but was less affected by adjustment (HR = 1.45, 95% CI: 1.25–1.68, p < 0.001).
- Limitation: 1. There were several tumor factors that were not available to include in the study, including estrogen receptor, progesterone receptor and HER - 2 status; performance status; or more detailed staging information.
3. **Prospective association of depression with survival: a population-based cohort study in patients with newly diagnosed breast cancer**

- **Year:** 2014
- **Journal:** Breast Cancer Research Treatment
- **Sample Population:** 1646 eligible patients with invasive female breast cancer stages I-IV from 2004 to 2009 (562 presented with depression symptoms, 260 of these patients met clinical levels of depression.
- **Conclusion:** Depression is strongly associated with mortality in younger patients with early stage breast cancer.
- **Depression Identification:** Patients were routinely assessed for emotional distress after cancer diagnosis but before treatment initiation. (Base on DSM-IV-TR criteria)
- **Results:** 1. (Stage I-III) Depression on all-cause mortality (HR=1.54, p=0.024), and breast cancer-specific mortality (HR=1.51, p=0.084). Age did not moderate association between depression and mortality. 2. Depression has an impact on all-cause and cancer-specific mortality in patients with stage I and Stage II (HR=2.5).
  3. Age moderates the association between depression and all-cause mortality in patients with stage I breast cancer. Younger patients at the age of 45 (HR=9.82) with a depression compared to non-depresses patients (HR=9.82, p= 0.002). Mean age of 57 (HR=3.69, p=0.007). 4. Analyses by tumor stage revealed that the effect of depression on mortality is mostly driven by patients with earlier stage breast cancer (stage I and Stage II).
- **Limitation:** 1. The relative brief depression measure does not substitute for a diagnosis of depression based on a structured clinical interview.

4. **Poor physical factors predict time to additional breast cancer events and mortality in breast cancer survivors**

- **Year:** 2011
- **Journal:** Psychology
- **Sample Population:** "Women with early stage breast cancer (n=2967) at 7 study sites between 1995 and 2000. Breast cancer diagnosis within the past 4 years of primary"
operable invasive stage I (≥ 1 cm), II, or IIIA breast carcinoma; age 18 – 70 years at time of diagnosis;

- Conclusion "Social support, optimism, hostility, and depression prior to randomization into a dietary trial were assessed. However, Except for hostility, none of the other psycho-social variables predicted either outcome.

- Depression Identification: "Depression was assessed by the 8-item Center for Epidemiologic Studies Depression screen (α =0.73). A value ≥ 0.06 in the logarithmic scale suggests clinical levels of depressive symptoms and the possibility of diagnosable mood disorder.

- Results: "Social support, optimism, hostility, and depression prior to randomization into a dietary trial were assessed. However, except for hostility, none of the other psycho-social variables predicted either outcome."

5. Psychosocial factors and survival of young women with breast cancer: a population-based prospective cohort study

- Year: 2008
- Journal: Journal of Clinical Oncology
- Sample Population: A population-based sample of 708 Australian women diagnosed before age 60 years with nonmetastatic breast cancer was observed for a median of 8.2 years. 73(3%) of these patients (HADs) were defined as with depression.

- Conclusion: There were no statistically significant associations between any of the measured psychosocial factors and distant disease-free survival or overall survival from the adjusted analyses. The findings do not support the measured psychosocial factors being an important influence on breast cancer outcomes.

- Depression Identification: Depression and anxiety, coping style, and social support were assessed at a median of 11 months after diagnosis using a face-to-face interview-participants were administered epidemiologic questionnaires.

- Results: 1. Greater anxious preoccupation was associated with younger age at diagnosis (P = .03), higher tumor grade (P = .02), and greater number of involved axillary nodes (P = .008). 2. Because the prevalence of probable depression (HADS score of > 10) was low (3%), analysis was repeated by, dichotomizing the HADS score at a cut point of 8 (possible or probable depression v depression unlikely), and the results did not change substantially (data not shown).
6. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer

- Year: 2004
- Journal: Journal of American Geriatric Society
- Sample Population: Women aged 67 to 90 diagnosed with breast cancer between 1993 and 1996 included in the SEER Medicare linked database. (N=24696, 7.5% with prior depression).
- Conclusion: Women with a recent diagnosis of depression are at greater risk for receiving nondefinitive treatment and experience worse survival after a diagnosis of breast cancer, but difference in treatment do not explain the worse survival.
- Depression Identification: 2 years before breast cancer diagnosis (identified by ICD-9-CM code).
- Results: 1. The women with a prior diagnosis of depression were on average older, more likely to be non-Hispanic white, less likely to be married, likely to have more comorbid illnesses. 2. There were no differences in tumor size at diagnosis in women with or without a prior diagnosis of depression. After controlling doctor visits, a diagnosis of depression was associated with increased size. 3. Women with a history of depression were significant less likely to receive standard cancer treatment. 4 Receipt of definitive treatment did not appear to mediate this increased risk of death associated with depression.
- Limitation: Only included women with breast cancer diagnosed at the age of 67 years or older, limiting the generalizability of result.

7. Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables

- Year: 2004
- Journal: Journal of Clinical Oncology
- Sample Population: 397 women diagnosed with breast cancer at participating University of Toronto teaching hospitals between 1991 and 1996 (younger than 75, with T1 to T3, N0/N1, M0 breast cancer.
- Conclusion: health-related quality of life (HRQOL) and psychosocial status at diagnosis and 1 year later are not associated with medical outcome in women with early-stage BC.
• Depression Identification: Based on self-report questionnaire to identify distress status.
• Results: Little convincing evidence was found that HRQOL or the psychosocial variables studied have important associations with distant disease-free survival (DDFS) or overall survival (OS) in women with newly diagnosed locoregional breast cancer.
• Limitation: 1. measure of mood (POMS) provides scores for depression and anxiety, these scores are not intended to be measures of clinical depression or anxiety.
2. Physiologic, compliance-related mechanisms, or social support in this research.
Initial Analysis Plan

Outline:

- Purpose
  1. To determine whether getting depression is associated with urban-rural/Appalachia-non-Appalachia status among breast cancer survivors;
  2. To determine whether diagnosed with depression is associated with breast cancer treatment;
  3. To examine the association between depression treatment and urban-rural/Appalachia-non-Appalachia status among breast cancer survivors diagnosed with depression;
  4. To find whether depression predicts worse survival among breast cancer survivors.

- Data source: The Kentucky Cancer Registry (KCR) linked data, American Community Survey (ACS) census tract file.

- Study population

- Key variables
  1. Depression Status (yes or no)
  2. Treatment of depression
  3. Cancer survival
  4. Cancer treatment
  5. Rural/urban status
  6. Appalachia-Non-Appalachia status

- Other independent variables

- Statistical analysis: Chi-square; Logistic Regression; Cox Regression Model
Selection Criterion

- Cancer cases: First Primary female breast cancer survivors age >=20, diagnosed at 2007-2011;
- Claims Data: Linked medicare, Medicaid, and private insurance claims data, 2006-2013;
- Continuous enrollment: Not required yet. Indicator variable which indicates enrollment is needed, including 12 months prior, 12 months after.
- Claims to define depression: 13 months (Month at the cancer diagnosis and 12 months after the diagnosis).
- The current plan is to include all patients who had depression after cancer diagnosis from claims; for these without depression, only include patients who had continuous coverage.

Variables and definitions

Depression status (Yes or no Identified by ICD-9-CM code):

- Major depressive disorder, single episode: 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26;
- Major depressive disorder, recurrent episode: 296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36;
- Depressive type psychosis: 298.0;
- Neurotic depression: 300.4;
- Adjustment disorder with depressed mood: 309.0;
- Prolonged depressive reaction: 309.1;
- Depressive disorders, not classified: 311.0.

Depression status will be calculated for both prior cancer diagnosis and after cancer diagnosis. Psychotherapy (Based on the following code to identify whether patients received Psychotherapy or not).

❖ Revenue center codes: This only works for Medicare data (output file only)

0114(Private medical or general-psychiatric)
0124(Semi-private 2 bed (medical or general)-psychiatric)
0134(Semi-private 3 and 4 beds-psychiatric)
0144(Private (deluxe)-psychiatric)
0154(Room & Board ward (medical or general)-psychiatric)
0204(Intensive care-psychiatric)
Provider specialty: The codes are different by claims sources

- Medicare—NCH, DME hcfapec

26(Psychiatry)
27(Geriatric psychiatry)
62(Psychologist)
68(Clinical psychologist)
86(Neuropsychiatry);

- Medicaid- PROV_SPEC
011 - Psychiatric  011 - Psychiatric
112 - Psychologist  112 - Psychologist
339 - Psychiatrist  339 - Psychiatrist
899 - Psychologist Group  899 - Psychologist Group

- Humana- Provider Spcty
103T00000X  103T00000X  Psychologist
103TA0400X  103TA0400X  Psychologist Addiction-Substance Use
103TA0700X  103TA0700X  Psychologist Adult Development & Aging
103TB0200X  103TB0200X  Psychologist Behavioral
103TC0700X  103TC0700X  Psychologist Clinical
103TC1900X  103TC1900X  Psychologist Counseling
103TC2200X  103TC2200X  Psychologist Child, Youth & Family
103TE1000X  103TE1000X  Psychologist Educational
103TE1100X  103TE1100X  Psychologist Exercise & Sports
103TF0000X  103TF0000X  Psychologist Family
103TF0200X  103TF0200X  Psychologist Forensic
102L00000X  102L00000X  PSYCHOANALYST
103G00000X  103G00000X  Neuropsychologist
103GC0700X  103GC0700X  Neuropsychologist Clinical
103TH0100X 103TH0100X Psychologist Health
103TM1700X 103TM1700X Psychologist Men & Masculinity
103TM1800X 103TM1800X Psychologist Mental Retardation & Dev
103TP0814X 103TP0814X Psychologist Psychoanalysis
103TP2700X 103TP2700X Psychologist Psychotherapy
103TP2701X 103TP2701X Psychologist Psychotherapy, Group
103TR0400X 103TR0400X Psychologist Rehabilitation
103TS0200X 103TS0200X Psychologist School
103TW0100X 103TW0100X Psychologist Women
163WP0808X 163WP0808X Reg Nurse Psych/Mental Health
163WP0809X 163WP0809X Reg Nurse Psych/Mental Health-Adult
167G00000X 167G00000X Licensed Psychiatric Technician
1835P1300X 1835P1300X Pharmacist Psychopharmacy
2084A0401X 2084A0401X Psychiatry & Neurology Addiction Medicine
2084B0002X 2084B0002X BARIATRIC MEDICINE
2084D0003X 2084D0003X DIAGNOSTIC NEUROIMAGING
2084F0202X 2084F0202X Psychiatry & Neurology Forensic Psychiat
2084N0400X 2084N0400X Psychiatry & Neurology
2084N0402X 2084N0402X Psychiatry & Neurology Child Neuro
2084N0600X 2084N0600X Psychiatry & Neurology Clinical Neurophy
2084P0005X 2084P0005X Psychiatry & Neurology Neurodevelopment
2084P0015X 2084P0015X PSYCHOSOMATIC MEDICINE
2084P0800X 2084P0800X Psychiatry & Neurology Psychiatry
2084P0802X 2084P0802X Psychiatry & Neurology Addiction Psych
2084P0804X 2084P0804X Psychiatry & Neurology Child & Adolesc
2084P0805X 2084P0805X Psychiatry & Neurology Geriatric Psych
2084P2900X 2084P2900X Psychiatry & Neurology Pain Medicine
2084SO010X  2084SO010X  Psychiatry & Neurology Sports Medicine
2084VO0102X  2084VO0102X  Psychiatry & Neurology Vascular Neurolog
273R00000X  273R00000X  Psychiatric Unit
283Q00000X  283Q00000X  Psychiatric Hospital
323P00000X  323P00000X  Psychiatric Residential Treatment Fac
363LP0808X  363LP0808X  Nurse Practitioner Psych/Mental Health
364SP0808X  364SP0808X  Clinical Nurse Spec Psych/Mental
364SP0809X  364SP0809X  Clinical Nurse Spec Psych/Mental Adult
364SP0810X  364SP0810X  Clin Nurse Spec Psych/Mental Child-Fam
364SP0811X  364SP0811X  Clin Nurse Spec Psych/Mental Chron Ill
364SP0812X  364SP0812X  Clin Nurse Spec Psych/Mental Community
364SP0813X  364SP0813X  Clin Nurse Spec Psych/Mental Geropsych

oAnthem-- HCIProvSpec
26 psychiatry;

❖ **CPT codes:**
90804–90829
90847: Family psychotherapy (conjoint psychotherapy) (with patient present)
90849: Multiple-family group psychotherapy
90853: Group psychotherapy (other than of a multiple family group)
90857: Interactive group psychotherapy
90865: Under Other Psychiatric Services or Procedures.
90870: Under Other Psychiatric Services or Procedures
G0409: Social work and psychological services, directly relating to and/or furthering the patient's rehabilitation goals, each 15 minutes, face-to-face; individual (services provided by a corf-qualified social worker or psychologist in a corf).

G0410: Group psychotherapy other than of a multiple-family group, in a partial hospitalization setting, approximately 45 to 50 minutes

G0411: Interactive group psychotherapy, in a partial hospitalization setting, approximately 45 to 50 minutes.

❖ Antidepressant Usage (Identified by using National Drug Codes)

Variables included:

- Depression status
- County
- Census Tract
- Race
- Smoking status (both kcr and augmented)
- Marital Status
- County Beale code
- Urban/Rural status
- Insurance Type
- Appalachian status
- Age at diagnosis
- Year of Diagnosis
- Diagnostic Confirmation
- Class of Case
- ER, PR and HER2 status (csfactor1-16
  http://web2.facs.org/cstage0205/breast/Breastschema.html)
- Best Stage
- Tumor Size
- Grade
- Histology code
- Behavior code
- Sequence number
- First course treatment (FstTrrtCompCode)
- Surgery code (RXSummSurgPrimSite)
- Radiation Therapy: Yes or no (both KCR and augmented, same for chemo, horm and surg)
- Chemotherapy: Yes or no
- Hormonal Therapy: Yes or no
o Carlson Comorbidity Index score (CCI, if do not have 12 months continuous enroll and no claims information then consider as missing)
o Survival status(vitalstat)
o Follow-up time(survival_month)
o County education and below poverty status

Index:
o 14 months continuous enroll: 1 month prior to 12 months after
o 13 months continuous enroll: month of diagnosis to 12 months after
o 12 months continuous enroll: 12 months prior cancer diagnosis
o Subsequent cancer within 1 year
o Smoking 12 months: capture smoking status using claims 12 months prior cancer diagnosis
o Smoking 25 months: capture smoking status using claims 12 months prior and 12 months after
Breast Cancer Guideline Treatment Algorithm

The treatment available in KCR:

Surgery, Chemotherapy, Radiation, Immunotherapy, Hormone therapy, except Surgery, most other therapy known as Yes or NO with a starting date.

Stage 0:

Main treatment (one of the following)

- Lumpectomy + followed irradiation + hormone therapy
- Mastectomy

Stage I&II:

Main treatment (one of the following)

- Lumpectomy + followed irradiation
- Mastectomy.

Additional treatment

- If patients have hormone receptor-positive (ER-positive or PR-positive) breast cancer, hormone therapy is included as standard care, and whether to receive chemotherapy depends on genomic analysis of the tumor (such as OncotypeDX). Since OncotypeDX is not available in standard KCR data, hormone therapy will be considered as standard care for ER, PR positive.
- If the cancer is HER2-positive, treatment with trastuzumab (Immunotherapy) should be given.
- If the cancer is not hormone receptor-positive, chemotherapy is given.

Stage III:

Main treatment (one of the following)

- Begin with any neoadjuvant therapy (Chemotherapy, and/or hormone therapy, and/or trastuzumab (Immunotherapy), followed with lumpectomy/mastectomy, followed by radiation
- Begin with surgery. Followed with Mastectomy + adjuvant chemotherapy, and/or hormone therapy, and/or trastuzumab (Immunotherapy).
Additional treatment

- If patients have hormone receptor-positive (ER-positive or PR-positive, HER2 negative) breast cancer, hormone therapy is included as standard care.
- If the cancer is HER2-positive, treatment with trastuzumab (Immunotherapy) should be given.

Stage IV:

- Hormone receptor-positive and HER2 negative cancers: hormone therapies are used for as long as possible before chemotherapy is introduced.
- HER2-positive cancers: Trastuzumab/Herceptin (Immunotherapy is given along with chemotherapy)
- Hormone receptor-negative cancers: Chemotherapy is the main treatment.
- How about surgery or radiation?
References

SAS CODES

Creating Formats for Categorical Variables

```
proc format lib=out.formats;
value appalf
  0="Non-Appal"
  1="Appal";
value smokerf
  0="Non-smoker"
  1='Smoker'
  9='Unknown';
value stagef
  0="Stage 0"
  1='Stage I'
  2='Stage II'
  3='Stage III'
  4='Stage IV'
  9='Unknown,N/A';
value seqcasef
  0="No"
  1="Yes";
value indicatorf
  0="No"
  1="Yes"
  9='Unknown';
value treatclaimf
  1='Yes';
value treatkcrf
  1='Yes';
value chalsonf
  -1='Missing'
  0="0"
  1="1"
  2=">2";
value hormonef
  -1='Missing'
  1='Positive/Elevated'
  2='Negative'
  9='Unknown';
value tumorsizef
  -1='Missing'
  1="<2"
  2="2-<5"
  3=">=5"
  9='Unknown,N/A';
value agef
  1='21-49'
  2='50-65'
  3='65-74'
  4='75+';
value diagconf
  1='Histology'
  2='Imaging/Clinical'
  9='Unknown';
```
value $ firsttreatmentf
  0 = 'No Definitive Therapy or Surgery at Regional and/or Distant Sites only'
  1 = 'Surgery at Primary Site Only'
  2 = 'Chemotherapy Only'
  3 = 'Surgery at Primary Site/Chemotherapy'
  4 = 'Radiation Therapy Only'
  5 = 'Surgery at Primary Site/Radiation Therapy'
  6 = 'Chemotherapy/Radiation Therapy'
  7 = 'Surgery at Primary Site/Chemo/Radiation Therapy'
  8 = 'Other Therapy Only'
  9 = 'Surgery at Primary Site/Other Therapy'
 10 = 'Chemotherapy/Other Therapy'
 11 = 'Surgery at Primary Site/Chemo/Other Therapy'
 12 = 'Radiation/Other Therapy'
 13 = 'Surgery at Primary Site/Radiation/Other Therapy'
 14 = 'Chemo/Radiation/Other Therapy'
 15 = 'Surgery at Primary Site/Chemo/Radiation/Other Therapy'
 64 = 'Unknown if or what therapy received';

value gradef
  1 = 'Well'
  2 = 'Moderate'
  3 = 'Poorly/Undifferentiated'
  9 = 'Unknown';

value maritalf
  1 = 'Married'
  2 = 'Never Married'
  3 = 'Separated/Divorced/Widowed'
  9 = 'Unknown';

value metrof
  0 = 'Non-metro'
  1 = 'Metro';

value pcharlsonf
  -1 = 'Missing'
  0 = '0'
  1 = '1'
  2 = '>=2';

value racef
  1 = 'White'
  2 = 'Non-white'
  9 = 'Unknown';

value surgerytypef
  0 = 'NO'
  1 = 'Mastectomy'
  2 = 'Lumpectomy'
  9 = 'Unknown';

value urbanf
  1 = 'Urban'
  0 = 'Rural';

value vitalstatf
  0 = 'Dead'
  1 = 'Alive';

value $ tobaccof
  0 = "Non-smoker"
  1 = 'Smoker'
  9 = 'Unknown';
value highschoolf
  1='<65'
  2='65%<=<75'
  3='75%<=<85'
  4='>=85'
  9='Unknown'
value povertyf
  1='<5'
  2='5%<=<10'
  3='10%<=<20'
  4='>=20'
  9='Unknown'
value newmetrof
  1='Metro'
  2='Rural'
  3='Isolated'
value stagegrpf
  0='Stage 0'
  1='Stage I&II'
  2='Stage III&IV'
  9='Unknown,N/A'
value cancertainmentf
  0='No'
  1='Yes'
  9='unknown'
value depressionf
  0='No depression'
  1='Pre&Pro depression'
  2='Pre depression only'
  3='Post depression only'
  9='Unknown'
value insurancef
  0='No insurance'
  1='Medicare'
  2='Medicaid/Other Public'
  3='Private insurance'
  9='Unknown'
run;
Format Assignment

```plaintext
options fmtsearch=(in.formats);

data in.breast_capstonewithformat;
set in.breast_capstone;
format appal appalf.
   AUGMENTED_FINALSMOKE_12M smokerf.
   AUGMENTED_FINALSMOKE_25M smokerf.
   STAGE stagef.
   CENT_TIME_A indicatorf.
   CENT_TIME_B indicatorf.
   CHEMO_AUGMENTED indicatorf.
   CHEMO_KCR treatkrf.
   CHARLSONGRP chalsonf.
   ER hormonef.
   PR hormonef.
   HER2 hormonef.
   TUMORSIZE tumorsizef.
   DEPRESSION_STATUS indicatorf.
   DEP_TIME_A indicatorf.
   DEP_TIME_B indicatorf.
   DIAGAGEGRP agef.
   DIAGCONFIRMGRP diagconf.
   DRUG_TIME_A indicatorf.
   DRUG_TIME_B indicatorf.
   ENROLL_14MON indicatorf.
   FSTTRTCOMPCODE firsttreatmentf.
   GRADE gradef.
   HCPCS_TIME_A indicatorf.
   HCPCS_TIME_B indicatorf.
   psychotherapy_TIME_A indicatorf.
   psychotherapy_TIME_B indicatorf.
   HORM_AUGMENTED indicatorf.
   HORM_KCR treatkrf.
   INDEX_1CLAIM indicatorf.
   INDEX_ENROLL_12PRIOR indicatorf.
   INDEX_ENROLL_13AFTER indicatorf.
   INDEX_SUBSEQCASE indicatorf.
   MARITALGRP maritalf.
   METRO metorf.
   PCHARLSONGRP pcharlsonf.
   PROVD_TIME_A indicatorf.
   PROVD_TIME_B indicatorf.
   RACE racef.
   RAD_AUGMENTED indicatorf.
   RAD_KCR treatkrf.
   SURGERYTYPE surgerytypef.
   SURG_AUGMENTED indicatorf.
   SURG_KCR treatkrf.
   TOBACCO tobaccof.
   TREAT_CENT indicatorf.
   TREAT_HCPCS indicatorf.
   TREAT_NDC indicatorf.
   TREAT_PROVD indicatorf.
```
Merging Census Tract Related Information with Primary Data

PROC IMPORT OUT= WORK.census_tract
    DATAFILE= "Z:\FeiTong Lei\Capstone\depression breast cancer\depression breast cancer\tract,patient_id.xlsx"
    DBMS=EXCEL REPLACE;
    RANGE="Sheet1$";
    GETNAMES=YES;
    MIXED=NO;
    SCANTEXT=YES;
    USEDATETIME=YES;
    SCANTIME=YES;
RUN;

libname in 'Z:\FeiTong Lei\Capstone\depression breast cancer\Data';

proc sort data=census_tract;
    by patient_id;
run;

proc sort data=in.breast_capstonewithformat;
    by patient_id;
run;

data in.allcases;
    merge census_tract in.breast_capstonewithformat;
    by patient_id;
run;

***************MERGE INCOME AND EDUCATION INFORMATION BY CENSUS TRACT****;

data capstone_allcases;
    set in.allcases;
    GEOID=cat(county,tract);
run;
libname ct 'Z:\FeiTong Lei\Medicare\Data\Census Tract\updated_datasets';
  data kyc2000;
  set ct.kyc2000;
  GEOID=cat(state,county,tract);
  keep GEOID CTMED POV_TOT HS_TOT;
run;
proc sort data=capstone_allcases;
  by GEOID;
run;
proc sort data=kyct2000;
  by GEOID;
run;
data in.capstone_allcases;
merge capstone_allcases kyct2000;
  by GEOID;
run;

Data Cleaning and Data Management
libname in 'Z:\FeiTong Lei\Capstone\depression breast cancer\Data';
options fmtsearch=(informats);

data primarycases;
set in.capstone_allcases;
where centralsequencenumber in (0,1);
run;

proc format;
  value depressionf
    0='No depression'
    1='Pre&Pro depression'
    2='Pre depression only'
    3='Post depression only'
    9='Unknown';
run;

*************Data complementary*****;

data primarycases;
set primarycases;

**********Create a variable to indicate time recived psychotherapy before or after cancer diagnosis****;
if cent_time_a=1 or hcpcs_time_a=1 or provd_time_a=1 then
  psychotherapy_time_a=1;
if cent_time_b=1 or hcpcs_time_b=1 or provd_time_b=1 then
  psychotherapy_time_b=1;

**********Create a variable to indicate whethere psychotherapy recieved**;
if Treat_cent=1 or treat_hcpcs=1 or treat_provd=1 then treat_psychotherapy=1;

******Stage Group***********;
if beststagegrp ge 0 and beststagegrp lt 10 then stage = 0;
else if beststagegrp ge 10 and beststagegrp lt 30 then stage=1;
else if beststagegrp ge 30 and beststagegrp lt 50 then stage=2;
else if beststagegrp ge 50 and beststagegrp lt 70 then stage=3;
else if beststagegrp ge 70 and beststagegrp le 80 then stage=4;
else if beststagegrp in (88,99) then stage=9;

*********Early Stage or else****;
if stage in (1,2) then stagegrp =1;
else if stage in (3,4) then stagegrp=2;
else if stage in(0) then stagegrp=0;
else stagegrp =9;

********tumorsize*********;
if cstumorsize in (998,999) then tumorsize=9;
else if cstumorsize ge 0 and cstumorsize lt 200 then tumorsize=1;
else if cstumorsize ge 200 and cstumorsize lt 500 then tumorsize=2;
else if cstumorsize in (990,991,992,996,997) then tumorsize=1;
else if cstumorsize in (993,994,995) then tumorsize=2;
else if cstumorsize ge 500 and cstumorsize le 989 then tumorsize=3;
else tumorsize=-1;

*********Charlson index***;
if chrlson =0 then charlsongrp=0;
else if chrlson = 1 then charlsongrp=1;
else if chrlson ge 2 then charlsongrp=2;
else charlsongrp=-1;

**********ER Status*****;
if csfactor1 in (10) then ER=1;
else if csfactor1 in (20) then ER=2;
else if csfactor1 in (30,996,997,998,999) then ER=9;

**********PR Status*****;
if csfactor2 in (10) then pr=1;
else if csfactor2 in (20) then pr=2;
else if csfactor2 in (30,996,997,998,999) then pr=9;

*****Hormone receptor status****;
if er = 1 or pr =1 then Hormone_receptor =1;
else if er =2 and pr=2 then Hormone_receptor=2;
else Hormone_receptor=9;

**********HER2 Status*****;
if csfactor15 in (10) then HER2=1;
else if csfactor15 in (20) then HER2=2;
else if csfactor15 in (30,996,997,998,999) then HER2=9;
else HER2=-1;

**********Diagnostic age group*****;
if diagage gt 0 and diagage le 49 then DIAGAGEGRP=1;
else if diagage ge 50 and diagage le 64 then diagagegrp=2;
else if diagage ge 65 and diagage le 74 then diagagegrp=3;
else if diagage ge 75 then diagagegrp=4;

**********Diagconfirmation*****;
if diagconfirm in (1,3) then diagconfirmgrp=1;
else if diagconfirm in (2,4,5,6,7,8) then diagconfirmgrp=2;
else if diagconfirm in (9) then diagconfirmgrp=9;

**********Marital group*****
if maritalstatus in (2,6) then maritalgrp=1;
else if maritalstatus in (1) then maritalgrp=2;
else if maritalstatus in (3,4,5) then maritalgrp=3;
else if maritalstatus in (9) then maritalgrp =9;

********Prior Charlson score******;
if pchrlson =0 then pcharlsongrp=0;
else if pchrlson = 1 then pcharlsongrp=1;
else if pchrlson ge 2 then pcharlsongrp=2;
else pcharlsongrp = -1;

********Race*******;
if racel in (1,3) then race =1;
else if racel in (2,4,5,6,8,10,15,16,96,98,97) then race=2;
else if racel in (99) then race =9;

*******Grade*******;
if grade =1 then gradegrp=1;
else if grade=2 then gradegrp=2;
else if grade in (3,4) then gradegrp=3;
else gradegrp=9;

******Surgery type******;
if rxsummsurgprimsite in (0) then surgerytype =0;
else if rxsummsurgprimsite ge 20 and rxsummsurgprimsite lt 30 then surgerytype =2;
else if rxsummsurgprimsite ge 30 and rxsummsurgprimsite le 80 then surgerytype =1;
else if rxsummsurgprimsite in (90,99) then surgerytype =9;

*****Below high school*****;
if hs_tot ge 0 and hs_tot lt 65 then highschool_or_more=1;
else if hs_tot ge 65 and hs_tot lt 75 then highschool_or_more=2;
else if hs_tot ge 75 and hs_tot lt 85 then highschool_or_more=3;
else if hs_tot ge 85 then highschool_or_more=4;
else highschool_or_more=9;

******Below Poverty**********;
if pov_tot ge 0 and pov_tot lt 5 then below_poverty=1;
else if pov_tot ge 5 and pov_tot lt 10 then below_poverty=2;
else if pov_tot ge 10 and pov_tot lt 20 then below_poverty=3;
else if pov_tot ge 20 then below_poverty=4;
else below_poverty=9;

*******Metro,rural status*****;
if beale_code03 in (1,2,3) then new_metro=1;
else if beale_code03 in (4,5,6) then new_metro=2;
else if beale_code03 in (7,8,9) then new_metro=3;

********Time before cancer diagnosis(NO/Unknown)*****;
if dep_time_b ne 1 and index_enroll 12prior=1 then dep_time_b=0;
else if dep_time_b ne 1 and index_enroll 12prior ne 1 then dep_time_b=9;

if psychotherapy_time_b ne 1 and index_enroll 12prior =1 then
psychotherapy_time_b=0;
else if psychotherapy_time_b ne 1 and index_enroll 12prior ne 1 then
psychotherapy_time_b=9;

if drug_time_b ne 1 and index_enroll 12prior =1 then drug_time_b=0;
else if drug_time_b ne 1 and index_enroll 12prior ne 1 then drug_time_b=9;
*****Time after cancer diagnosis(NO/Unknown)********;
if dep_time_a ne 1 and index_enroll_13after=1 then dep_time_a=0;
else if dep_time_a ne 1 and index_enroll_13after ne 1 then dep_time_a=9;

if psychotherapy_time_a ne 1 and index_enroll_13after=1 then
psychotherapy_time_a=0;
else if psychotherapy_time_a ne 1 and index_enroll_13after ne 1 then
psychotherapy_time_a=9;
else if psychotherapy_time_a ne 1 then
psychotherapy_time_a=9;

if drug_time_a ne 1 and index_enroll_13after=1 then
drug_time_a =0;
else if drug_time_a ne 1 and index_enroll_13after ne 1 then
drug_time_a=9;
else if drug_time_a =ne 1 then
drug_time_a =9;

if psychotherapy_time_a=1 or drug_time_a=1 then depression_trt_after=1;
else if psychotherapy_time_a=0 and drug_time_a =0 then
depression_trt_after=0;
else depression_trt_after=9;

******depression status(no/unknown)***;
if dep_time_b =0 and dep_time_a=0 then depression_status=0;
else if depression_status ne 1 then depression_status=9;

**********Cancer treatment**********;
if chemo_augmented=1 then chemo=1;
else if chemo_augmented ne 1 and index_enroll_13after=1 then chemo=0;
else if chemo_augmented ne 1 and index_enroll_13after ne 1 then chemo=9;

if horm_augmented=1 then horm=1;
else if horm_augmented ne 1 and index_enroll_13after=1 then horm=0;
else if horm_augmented ne 1 and index_enroll_13after ne 1 then horm=9;

if rad_augmented=1 then rad=1;
else if rad_augmented ne 1 and index_enroll_13after=1 then rad=0;
else if rad_augmented ne 1 and index_enroll_13after ne 1 then rad=9;

if surg_augmented=1 then surg=1;
else if surg_augmented ne 1 and index_enroll_13after=1 then surg=0;
else if surg_augmented ne 1 and index_enroll_13after ne 1 then surg=9;

*****Create a variable to indicate whether cancer treatment is
appropriate****;
******For hormone receptor status******;
/*if SURVIVAL_MONTH le 6 then appropriate_cancertreatment=-1;
else if SURVIVAL_MONTH gt 6 then do;*/

if hormone_receptor =1 and horm=1 then horm_standard=1;
else if hormone_receptor=1 and horm=0 then horm_standard=0;
else if hormone_receptor=2 and horm=1 then horm_standard=0;
else if hormone_receptor=2 and horm=0 then horm_standard=1;
else horm_standard=9;
******For stage 0*******;
if stage=0 and surgerytype=1 then surg_standard=1;
else if stage=0 and surgerytype=2 and rad=1 then surg_standard=1;
else if stage=0 and surgerytype=2 and rad=0 then surg_standard=0;
else if stage=0 and surgerytype=9 then surg_standard=9;
else if stage=0 and surgerytype=0 then surg_standard=0;

if stage=0 and surg_standard=1 and horm_standard=1 then
appropriate_cancertreatment=1;
else if stage=0 and (surg_standard=0 or horm_standard=0) then
appropriate_cancertreatment=0;
else if stage=0 and surg_standard=1 and horm_standard=9 then
appropriate_cancertreatment=9;
else if stage=0 and surg_standard=9 and horm_standard=1 then
appropriate_cancertreatment=9;

******For stage I&II*******;
if stage in (1,2) and surgerytype=0 then surg_standard=0;
else if stage in (1,2) and surgerytype=1 then surg_standard=1;
else if stage in (1,2) and surgerytype=2 and rad=1 then surg_standard=1;
else if stage in (1,2) and surgerytype=2 and rad=0 then surg_standard=0;
else if stage in (1,2) and surgerytype=2 and rad=9 then surg_standard=9;
else if stage in (1,2) then surg_standard=9;

if stage in (1,2) and hormone_receptor=9 then chemo_standard=9;
else if stage in (1,2) and hormone_receptor=2 and chemo=1 then chemo_standard=1;
else if stage in (1,2) and hormone_receptor=2 and chemo=0 then chemo_standard=0;
else if stage in (1,2) and hormone_receptor=2 and chemo=9 then chemo_standard=9;
else if stage in (1,2) then chemo_standard=9;

if stage in (1,2) then do;
if surg_standard=1 and horm_standard=1 and chemo_standard=1 then
appropriate_cancertreatment=1;
else if surg_standard=0 or horm_standard=0 or chemo_standard=0 then
appropriate_cancertreatment=0;
else if surg_standard=9 or horm_standard=9 or chemo_standard=9 then
appropriate_cancertreatment=9;
end;

*******For stage III***********;
****Begin with neoneoadjuvant therapy***;

if stage=3 then do;
*if chemo=1 and surg=1 and datesurg1 < datechemo1 and surgerytype =2 then
surg_standard=0;
if surg=1 then surg_standard=1;
else if surg=0 then surg_standard=0;
else if surg=9 then surg_standard=9;
if chemo=0 then chemo_standard=0;
else if chemo=1 then chemo_standard=1;
else if chemo=9 then chemo_standard=9;

if rad=0 then rad_standard=0;
else if rad=1 then rad_standard=1;
else if rad=9 then rad_standard=9;

if surg_standard=1 and horm_standard=1 and chemo_standard=1 and rad_standard=1 then appropriate_cancertreatment=1;
else if surg_standard=0 or horm_standard=0 or chemo_standard=0 or rad_standard=0 then appropriate_cancertreatment=0;
else if surg_standard=9 or horm_standard=9 or chemo_standard=9 or rad_standard=9 then appropriate_cancertreatment=9;
end;

******For stage IV***********;
if stage = 4 and hormone_receptor=2 and chemo=1 then chemo_standard=1;
else if stage = 4 and hormone_receptor=2 and chemo=0 then chemo_standard=0;
else if stage = 4 and hormone_receptor=1 then chemo_standard=1;

if stage=4 and horm_standard=1 and chemo_standard=1 then appropriate_cancertreatment=1;
else if stage=4 and ( horm_standard=0 or chemo_standard=0) then appropriate_cancertreatment=0;
else if stage=4 then appropriate_cancertreatment=9;

******Stage unknown*****;
if stage=9 then appropriate_cancertreatment=9;

label csfactor1='ER Status'
csfactor2='PR status'
csfactor3='HER2 Status'
dep_time_b='Depression diagnosed before cancer';
/*end;*/

******new category of depression****;
if dep_time_b=0 and dep_time_a=0 then depression=0;
else if dep_time_b=1 and dep_time_a=1 then depression=1;
else if dep_time_b=1 and dep_time_a=0 then depression=2;
else if dep_time_b=0 and dep_time_a=1 then depression=3;
else if dep_time_b =9 or dep_time_a=9 then depression=9;

*********Insurance type************;
if primarypayor in (1,2) then insurance_type=0;
else if primarypayor in (10,99) then insurance_type=9;
else if primarypayor in (60,61,62,63,64) then insurance_type=1;
else if primarypayor in (31,35,65,66,67,68) then insurance_type=2;
else if primarypayor in (20, 21) then insurance_type=3;

format highschool_or_more highschoolf. new_metro newmetrof. stagegrp stagegrpf. gradegrp gradef.
depression_trt_after indicatorf. appropriate_cancertreatment cancertainmentf. diagagegrp agef.
Hormone_receptor hormonef. chemo horm surg rad indicatorf. chemo_standard horm_standard surg_standard rad_standard indicatorf. depression depressionf.
insurance_type insurancef.;
run;

data in.analysis;
set primarycases;
run;

proc freq data=primarycases;
table appropriate_cancertreatment;
run;

data depression;
set primarycases;
where depression ^in (9) and stage ^ in (0);
run;

proc freq data=fullenrollment;
table appropriate_cancertreatment;
run;

Comparison between Patients Group Based on Depression Status
libname in 'C:\Users\walala\Desktop\Capstone\depression breast cancer\Data';
options fmtsearch=(in.formats);
ods pdf file='Z:\FeiTong Lei\Capstone\depression breast cancer\output\patients_character.pdf';

data depression;
set in.analysis;
where depression in (0,1,2,3) and stage in (1,2,3,4,9);
format race racef.;
run;

data depression_a;
set in.analysis;
where dep_time_a in (0,1) and stage in (1,2,3,4,9);
format race racef.;
run;

%macro sec(var);
proc freq data=fullenrollment;
table &var*depression/chisq;
where depression in (1,2);
run;

%mend;
%sec(RACE);
%sec(AUGMENTED_FINALSMOKE_12M);
%sec(DIAGAGEGRP);
%sec(APPAL);
%sec(MARITALGRP);
%sec(highschool_or_more);
%sec(below_poverty);
%sec(insurance_type);
%sec(CHARLSONGRP);
%sec(stage);
%sec(gradegrp);
%sec(Tumorsize);
%sec(appropriate_cancertreatment);

******Standard Treatment*****;
%macro sec(var);
proc freq data=in.fullenrollment;
table &var*appropriate_cancertreatment/chisq;
where appropriate_cancertreatment in (0,1);
run;
%mend;
%sec(RACE);
%sec(AUGMENTED_FINALSMOKE_12M);
%sec(DIAGAGEGRP);
%sec(APPAL);
%sec(MARITALGRP);
%sec(highschool_or_more);
%sec(below_poverty);
%sec(insurance_type);
%sec(CHARLSONGRP);
%sec(stage);
%sec(gradegrp);
%sec(Tumorsize);
%sec(depression);

**********Depression after Cancer*****;
%macro sec(var);
proc freq data=depression;
table depression*&var/chisq;
where depression in (0,3);
run;
%mend;
%sec(AUGMENTED_FINALSMOKE_12M);
%sec(APPAL);
Logistic Regression and Cox Regression

**PROC LOGISTIC**

```plaintext
PROC LOGISTIC data=in.fullenrollment;
class appropriate_cancertreatment(ref='Yes') DEP_TIME_B(REF='No')
DEP_TIME_A(REF='No') depression_status(ref='No') depression(ref='No depression')
AUGMENTED_FINALSMOKE_12M(ref='Non-smoker') APPAL (ref="Non-Appal")
urban(ref='Urban') Metro(ref='Metro') DIAGAGEGRP(ref='21-49')
MARITALGRP(ref='Married') RACE(ref='Non-white') STRATA (ref='1')
CHARLSONGRP(ref='0') PCHARLSONGRP(ref='0') ER
(ref='Positive/Elevated') hormone_receptor(ref='Positive/Elevated') GRADEgrp
(ref='Well') HER2(ref='Positive/Elevated') TUMORSIZE(ref="<2")
highschool_or_more(ref='>=85%') below_poverty(ref='<5%')
model appropriate_cancertreatment= depression APPAL highschool_or_more
insurance_type(ref='Private insurance')/param=glm;
where appropriate_cancertreatment in (0,1);
run;
```

**PROC PHREG**

```plaintext
proc phreg data=fullenrollment;
class depression_status(ref='No') depression(ref='No depression') dep_time_a
(ref='No') dep_time_b(ref='No') AUGMENTED_FINALSMOKE_12M(ref='Non-smoker')
APPAL (ref="Appal") surg_augmented (ref='Yes')
rad_augmented (ref='Yes') horm_augmented (ref='Yes') chemo_augmented
(ref='Yes')
urban(ref='Urban') Metro(ref='Metro') MARITALGRP(ref='Married')
RACE(ref='Non-white') STRATA (ref='1') CHARLSONGRP(ref='0')
PR(ref='Positive/Elevated') ER(ref='Positive/Elevated')
gradegrp(ref='Well') HER2(ref='Positive/Elevated')
TUMORSIZE(ref="<2") highschool_or_more(ref='>=85%')
below_poverty(ref='<5%') drug_time_a(ref='No') psychotherapy_time_a(ref='No')
new_metro(ref='Metro')
appropriate_cancertreatment(ref='Yes') DIAGAGEGRP(ref='21-49')
drug_time_a(ref='No') psychotherapy_time_a(ref='No') depression_trt_after
(ref='No') STAGE(ref="Stage I")
```
insurance_type(ref='Private insurance') /param=glm;
model Survival_month*Vitalstat(1)= depression APPAL AUGMENTED_FINALSMOKE_12M
highschool_or_more DIAGAGEGRP MARITALGRP insurance_type
STAGE CHARLSONGRP hormone_receptor grade grp
appropriate_cancertreatment ;
run;
Table 1. Patients Characteristics (n=6054)

<table>
<thead>
<tr>
<th>Factors</th>
<th>No depression (n=5212)</th>
<th>Pre&amp;Post depression (n=246)</th>
<th>Pre-depression only (n=221)</th>
<th>Post-depression only (n=375)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Pct</td>
<td>N</td>
<td>Pct</td>
<td>N</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>4869</td>
<td>85.93</td>
<td>237</td>
<td>4.18</td>
<td>212</td>
</tr>
<tr>
<td>Non-white</td>
<td>328</td>
<td>88.17</td>
<td>9</td>
<td>2.42</td>
<td>9</td>
</tr>
<tr>
<td>Unknown</td>
<td>15</td>
<td>93.75</td>
<td>0</td>
<td>0.00</td>
<td>0</td>
</tr>
<tr>
<td>Smoking Status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-smoker</td>
<td>2352</td>
<td>87.50</td>
<td>89</td>
<td>3.31</td>
<td>87</td>
</tr>
<tr>
<td>Smoker</td>
<td>1797</td>
<td>82.54</td>
<td>121</td>
<td>5.56</td>
<td>94</td>
</tr>
<tr>
<td>Unknown</td>
<td>1063</td>
<td>89.40</td>
<td>36</td>
<td>3.03</td>
<td>40</td>
</tr>
<tr>
<td>Age at Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21-49</td>
<td>440</td>
<td>80.29</td>
<td>34</td>
<td>6.20</td>
<td>20</td>
</tr>
<tr>
<td>50-65</td>
<td>1042</td>
<td>80.90</td>
<td>85</td>
<td>6.60</td>
<td>62</td>
</tr>
<tr>
<td>65-74</td>
<td>1920</td>
<td>86.96</td>
<td>78</td>
<td>3.53</td>
<td>73</td>
</tr>
<tr>
<td>75+</td>
<td>1810</td>
<td>90.05</td>
<td>49</td>
<td>2.44</td>
<td>66</td>
</tr>
<tr>
<td>Appalachian Status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Appal</td>
<td>3786</td>
<td>86.12</td>
<td>179</td>
<td>4.07</td>
<td>159</td>
</tr>
<tr>
<td>Appal</td>
<td>1426</td>
<td>86.01</td>
<td>67</td>
<td>4.04</td>
<td>62</td>
</tr>
<tr>
<td>Marital Status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>2558</td>
<td>87.84</td>
<td>110</td>
<td>3.78</td>
<td>97</td>
</tr>
<tr>
<td>Never Married</td>
<td>348</td>
<td>82.27</td>
<td>25</td>
<td>5.91</td>
<td>18</td>
</tr>
<tr>
<td>Separated/Divorced/Widowed</td>
<td>2133</td>
<td>84.91</td>
<td>100</td>
<td>3.98</td>
<td>103</td>
</tr>
<tr>
<td>Unknown</td>
<td>173</td>
<td>83.57</td>
<td>11</td>
<td>5.31</td>
<td>3</td>
</tr>
<tr>
<td>High school or more</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65%</td>
<td>1159</td>
<td>85.60</td>
<td>60</td>
<td>4.43</td>
<td>55</td>
</tr>
<tr>
<td>65%--&lt;75%</td>
<td>1324</td>
<td>86.09</td>
<td>59</td>
<td>3.84</td>
<td>52</td>
</tr>
<tr>
<td>75%--&lt;85%</td>
<td>1332</td>
<td>85.22</td>
<td>65</td>
<td>4.16</td>
<td>65</td>
</tr>
<tr>
<td>&gt;=85%</td>
<td>1383</td>
<td>87.31</td>
<td>62</td>
<td>3.91</td>
<td>49</td>
</tr>
<tr>
<td>Unknown</td>
<td>14</td>
<td>93.33</td>
<td>0</td>
<td>0.00</td>
<td>0</td>
</tr>
<tr>
<td>Below poverty</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5%</td>
<td>906</td>
<td>87.96</td>
<td>36</td>
<td>3.50</td>
<td>37</td>
</tr>
<tr>
<td>5%--&lt;10%</td>
<td>1317</td>
<td>85.91</td>
<td>73</td>
<td>4.76</td>
<td>53</td>
</tr>
<tr>
<td>%10--&lt;20%</td>
<td>1566</td>
<td>85.67</td>
<td>64</td>
<td>3.50</td>
<td>67</td>
</tr>
<tr>
<td>&gt;=20%</td>
<td>1409</td>
<td>85.50</td>
<td>73</td>
<td>4.43</td>
<td>64</td>
</tr>
<tr>
<td>Unknown</td>
<td>14</td>
<td>93.33</td>
<td>0</td>
<td>0.00</td>
<td>0</td>
</tr>
<tr>
<td>Factors</td>
<td>No depression (n=5212)</td>
<td>Pre&amp;Post depression (n=246)</td>
<td>Pre depression only (n=221)</td>
<td>Post-depression only (n=375)</td>
<td>P-value</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------</td>
<td>----------------------------</td>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Primary payer</td>
<td>N</td>
<td>Pct</td>
<td>N</td>
<td>Pct</td>
<td>N</td>
</tr>
<tr>
<td>No insurance</td>
<td>7</td>
<td>87.50</td>
<td>1</td>
<td>12.50</td>
<td>0</td>
</tr>
<tr>
<td>Medicare</td>
<td>3722</td>
<td>86.56</td>
<td>168</td>
<td>3.91</td>
<td>145</td>
</tr>
<tr>
<td>Medicaid/Other Public</td>
<td>266</td>
<td>77.10</td>
<td>33</td>
<td>9.57</td>
<td>28</td>
</tr>
<tr>
<td>Private insurance</td>
<td>1141</td>
<td>87.23</td>
<td>42</td>
<td>3.21</td>
<td>42</td>
</tr>
<tr>
<td>Unknown</td>
<td>76</td>
<td>81.72</td>
<td>2</td>
<td>2.15</td>
<td>6</td>
</tr>
<tr>
<td>Charlson Score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Missing</td>
<td>217</td>
<td>97.31</td>
<td>1</td>
<td>0.45</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>3075</td>
<td>87.91</td>
<td>111</td>
<td>3.17</td>
<td>102</td>
</tr>
<tr>
<td>1</td>
<td>1132</td>
<td>84.41</td>
<td>62</td>
<td>4.62</td>
<td>53</td>
</tr>
<tr>
<td>&gt;=2</td>
<td>788</td>
<td>79.44</td>
<td>72</td>
<td>7.26</td>
<td>66</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>2473</td>
<td>87.35</td>
<td>108</td>
<td>3.81</td>
<td>98</td>
</tr>
<tr>
<td>Stage II</td>
<td>1560</td>
<td>84.23</td>
<td>87</td>
<td>4.70</td>
<td>65</td>
</tr>
<tr>
<td>stage III</td>
<td>588</td>
<td>83.40</td>
<td>34</td>
<td>4.82</td>
<td>28</td>
</tr>
<tr>
<td>Stage IV</td>
<td>348</td>
<td>90.39</td>
<td>9</td>
<td>2.34</td>
<td>16</td>
</tr>
<tr>
<td>Unknown,N/A</td>
<td>243</td>
<td>86.48</td>
<td>8</td>
<td>2.85</td>
<td>14</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>1129</td>
<td>86.98</td>
<td>52</td>
<td>4.01</td>
<td>38</td>
</tr>
<tr>
<td>Moderate</td>
<td>2172</td>
<td>85.92</td>
<td>101</td>
<td>4.00</td>
<td>96</td>
</tr>
<tr>
<td>Poorly/Undifferentiated</td>
<td>1480</td>
<td>85.65</td>
<td>75</td>
<td>4.34</td>
<td>59</td>
</tr>
<tr>
<td>Unknown</td>
<td>431</td>
<td>86.20</td>
<td>18</td>
<td>3.60</td>
<td>28</td>
</tr>
<tr>
<td>Tumor Size (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td>4926</td>
<td>86.19</td>
<td>230</td>
<td>4.02</td>
<td>204</td>
</tr>
<tr>
<td>2-&lt;5</td>
<td>19</td>
<td>73.08</td>
<td>2</td>
<td>7.69</td>
<td>2</td>
</tr>
<tr>
<td>&gt;=5</td>
<td>2</td>
<td>66.67</td>
<td>1</td>
<td>33.33</td>
<td>0</td>
</tr>
<tr>
<td>Unknown,N/A</td>
<td>265</td>
<td>85.48</td>
<td>13</td>
<td>4.19</td>
<td>15</td>
</tr>
<tr>
<td>Standard Cancer Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>1523</td>
<td>86.05</td>
<td>69</td>
<td>3.90</td>
<td>79</td>
</tr>
<tr>
<td>Yes</td>
<td>3256</td>
<td>85.93</td>
<td>161</td>
<td>4.25</td>
<td>122</td>
</tr>
<tr>
<td>unknown</td>
<td>433</td>
<td>87.47</td>
<td>16</td>
<td>3.23</td>
<td>20</td>
</tr>
</tbody>
</table>

FEITONGLIE@GMAIL.COM 34
## Table 2. Standard Treatment (n=5559)

<table>
<thead>
<tr>
<th>Factors</th>
<th>Nontheguideline Treatment (n=1770)</th>
<th>Guideline Treatment (n=3789)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Depression</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No depression</td>
<td>1523</td>
<td>3256</td>
<td>68.13</td>
</tr>
<tr>
<td>Pre/Post Depression</td>
<td>69</td>
<td>161</td>
<td>70.00</td>
</tr>
<tr>
<td>Pre-depression only</td>
<td>79</td>
<td>122</td>
<td>60.70</td>
</tr>
<tr>
<td>Post-depression only</td>
<td>99</td>
<td>250</td>
<td>71.63</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>1655</td>
<td>3541</td>
<td>68.15</td>
</tr>
<tr>
<td>Non-white</td>
<td>115</td>
<td>236</td>
<td>67.24</td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
<td>12</td>
<td>100.00</td>
</tr>
<tr>
<td><strong>Smoking Status</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>793</td>
<td>1725</td>
<td>68.51</td>
</tr>
<tr>
<td>Smoker</td>
<td>607</td>
<td>1454</td>
<td>70.55</td>
</tr>
<tr>
<td>Unknown</td>
<td>370</td>
<td>610</td>
<td>62.24</td>
</tr>
<tr>
<td><strong>Age at Diagnosis</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>21-49</td>
<td>77</td>
<td>448</td>
<td>85.33</td>
</tr>
<tr>
<td>50-65</td>
<td>227</td>
<td>986</td>
<td>81.29</td>
</tr>
<tr>
<td>65-74</td>
<td>535</td>
<td>1511</td>
<td>73.85</td>
</tr>
<tr>
<td>75+</td>
<td>931</td>
<td>844</td>
<td>47.55</td>
</tr>
<tr>
<td><strong>Appalachian Status</strong></td>
<td></td>
<td></td>
<td>0.5456</td>
</tr>
<tr>
<td>Non-Appal</td>
<td>1285</td>
<td>2780</td>
<td>68.39</td>
</tr>
<tr>
<td>Appal</td>
<td>485</td>
<td>1009</td>
<td>67.54</td>
</tr>
<tr>
<td><strong>Marital Status</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Married</td>
<td>677</td>
<td>2066</td>
<td>75.32</td>
</tr>
<tr>
<td>Never Married</td>
<td>124</td>
<td>272</td>
<td>68.69</td>
</tr>
<tr>
<td>Separated/Divorced/Widowed</td>
<td>917</td>
<td>1356</td>
<td>59.66</td>
</tr>
<tr>
<td>Unknown</td>
<td>52</td>
<td>95</td>
<td>64.63</td>
</tr>
<tr>
<td><strong>High school or more</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>&lt;65%</td>
<td>356</td>
<td>858</td>
<td>70.68</td>
</tr>
<tr>
<td>65%-&lt;75%</td>
<td>516</td>
<td>882</td>
<td>63.09</td>
</tr>
<tr>
<td>75%-&lt;85%</td>
<td>469</td>
<td>980</td>
<td>67.63</td>
</tr>
<tr>
<td>&gt;=85%</td>
<td>425</td>
<td>1062</td>
<td>71.42</td>
</tr>
<tr>
<td>Unknown</td>
<td>4</td>
<td>7</td>
<td>63.64</td>
</tr>
<tr>
<td><strong>Below poverty</strong></td>
<td></td>
<td></td>
<td>0.0076</td>
</tr>
<tr>
<td>&lt;5%</td>
<td>270</td>
<td>697</td>
<td>72.08</td>
</tr>
<tr>
<td>5%-&lt;10%</td>
<td>430</td>
<td>986</td>
<td>69.63</td>
</tr>
<tr>
<td>10%-&lt;20%</td>
<td>575</td>
<td>1102</td>
<td>65.71</td>
</tr>
<tr>
<td>&gt;=20%</td>
<td>491</td>
<td>997</td>
<td>67.00</td>
</tr>
<tr>
<td>Unknown</td>
<td>4</td>
<td>7</td>
<td>63.64</td>
</tr>
<tr>
<td><strong>Primary payer</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>No insurance</td>
<td>2</td>
<td>6</td>
<td>75.00</td>
</tr>
</tbody>
</table>
### Table 2. Standard Treatment (n=5559) (Cont.)

<table>
<thead>
<tr>
<th>Factors</th>
<th>Nonguideline Treatment (n=1770)</th>
<th>Guideline Treatment (n=3789)</th>
<th>p- value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Pct</td>
<td>N</td>
</tr>
<tr>
<td>Medicare</td>
<td>1476</td>
<td>37.24</td>
<td>2487</td>
</tr>
<tr>
<td>Medicaid/Other Public</td>
<td>90</td>
<td>27.61</td>
<td>236</td>
</tr>
<tr>
<td>Private insurance</td>
<td>192</td>
<td>15.46</td>
<td>1050</td>
</tr>
<tr>
<td>Unknown</td>
<td>10</td>
<td>50.00</td>
<td>10</td>
</tr>
<tr>
<td>Charlson Score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>64</td>
<td>32.48</td>
<td>133</td>
</tr>
<tr>
<td>0</td>
<td>905</td>
<td>27.83</td>
<td>2347</td>
</tr>
<tr>
<td>1</td>
<td>419</td>
<td>34.06</td>
<td>811</td>
</tr>
<tr>
<td>&gt;=2</td>
<td>382</td>
<td>43.41</td>
<td>498</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>900</td>
<td>32.91</td>
<td>1835</td>
</tr>
<tr>
<td>Stage II</td>
<td>444</td>
<td>24.61</td>
<td>1360</td>
</tr>
<tr>
<td>Stage III</td>
<td>355</td>
<td>51.01</td>
<td>341</td>
</tr>
<tr>
<td>Stage IV</td>
<td>71</td>
<td>21.91</td>
<td>253</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>371</td>
<td>30.46</td>
<td>847</td>
</tr>
<tr>
<td>Moderate</td>
<td>717</td>
<td>29.87</td>
<td>1683</td>
</tr>
<tr>
<td>Poorly/Undifferentiated</td>
<td>541</td>
<td>32.93</td>
<td>1102</td>
</tr>
<tr>
<td>Unknown</td>
<td>141</td>
<td>47.31</td>
<td>157</td>
</tr>
<tr>
<td>Tumor Size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td>1725</td>
<td>31.71</td>
<td>3714</td>
</tr>
<tr>
<td>2-&lt;5</td>
<td>9</td>
<td>39.13</td>
<td>14</td>
</tr>
<tr>
<td>&gt;=5</td>
<td>2</td>
<td>66.67</td>
<td>1</td>
</tr>
<tr>
<td>Unknown, N/A</td>
<td>34</td>
<td>36.17</td>
<td>60</td>
</tr>
</tbody>
</table>
Table 3. Multivariable logistic regression to identify the association between depression status and nonguideline cancer treatment.

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression Status</td>
<td></td>
<td></td>
<td>0.2815</td>
</tr>
<tr>
<td>Pre depression only</td>
<td>1.379</td>
<td>0.992</td>
<td>1.918</td>
</tr>
<tr>
<td>Post depression only</td>
<td>0.964</td>
<td>0.736</td>
<td>1.263</td>
</tr>
<tr>
<td>Pre &amp; Post depression</td>
<td>1.041</td>
<td>0.751</td>
<td>1.441</td>
</tr>
<tr>
<td>No Depression</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appalachian Status</td>
<td></td>
<td></td>
<td>0.0269</td>
</tr>
<tr>
<td>Appalachian</td>
<td>1.232</td>
<td>1.024</td>
<td>1.482</td>
</tr>
<tr>
<td>Non-Appalachian</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at Diagnosis</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>50-65</td>
<td>1.239</td>
<td>0.915</td>
<td>1.677</td>
</tr>
<tr>
<td>65-74</td>
<td>1.872</td>
<td>1.352</td>
<td>2.592</td>
</tr>
<tr>
<td>75+</td>
<td>5.929</td>
<td>4.252</td>
<td>8.266</td>
</tr>
<tr>
<td>21-49</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marital Status</td>
<td></td>
<td></td>
<td>0.0015</td>
</tr>
<tr>
<td>Never Married</td>
<td>1.361</td>
<td>1.054</td>
<td>1.757</td>
</tr>
<tr>
<td>Separated/Divorced/Widowed</td>
<td>1.294</td>
<td>1.125</td>
<td>1.489</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.275</td>
<td>0.858</td>
<td>1.894</td>
</tr>
<tr>
<td>Married</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High School or more</td>
<td></td>
<td></td>
<td>0.0002</td>
</tr>
<tr>
<td>&lt;65%</td>
<td>0.827</td>
<td>0.653</td>
<td>1.048</td>
</tr>
<tr>
<td>65%-&lt;75%</td>
<td>1.295</td>
<td>1.081</td>
<td>1.553</td>
</tr>
<tr>
<td>75%-&lt;85%</td>
<td>1.124</td>
<td>0.942</td>
<td>1.341</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.845</td>
<td>0.496</td>
<td>6.863</td>
</tr>
<tr>
<td>&gt;=85%</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary payer</td>
<td></td>
<td></td>
<td>0.0078</td>
</tr>
<tr>
<td>No insurance</td>
<td>1.887</td>
<td>0.352</td>
<td>10.127</td>
</tr>
<tr>
<td>Medicare</td>
<td>1.474</td>
<td>1.144</td>
<td>1.9</td>
</tr>
<tr>
<td>Medicaid/Other Public</td>
<td>1.734</td>
<td>1.245</td>
<td>2.413</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.845</td>
<td>0.496</td>
<td>6.863</td>
</tr>
<tr>
<td>Private insurance</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charlson Score</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>1</td>
<td>1.093</td>
<td>0.934</td>
<td>1.28</td>
</tr>
<tr>
<td>&gt;=2</td>
<td>1.58</td>
<td>1.325</td>
<td>1.884</td>
</tr>
<tr>
<td>Missing</td>
<td>1.375</td>
<td>0.953</td>
<td>1.985</td>
</tr>
<tr>
<td>0</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Stage II</td>
<td>0.539</td>
<td>0.464</td>
<td>0.626</td>
</tr>
<tr>
<td>Stage III</td>
<td>1.96</td>
<td>1.619</td>
<td>2.372</td>
</tr>
<tr>
<td>Stage IV</td>
<td>0.386</td>
<td>0.285</td>
<td>0.522</td>
</tr>
<tr>
<td>Stage I</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hormone Receptor</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Negative</td>
<td>2.762</td>
<td>2.349</td>
<td>3.247</td>
</tr>
<tr>
<td>Positive</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1. Survival curves in breast cancer patients grouped based on depression

![Figure 1. Survival curves in breast cancer patients grouped based on depression](image)
Figure 2. Survival curves in breast cancer patients grouped based on Appalachian Status
Tables 4. Adjusted Cox hazard regression to identify the association between depression and survival.

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Depression Status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre depression only</td>
<td>1.23</td>
<td>0.97</td>
<td>1.56</td>
</tr>
<tr>
<td>Post depression only</td>
<td>1.50</td>
<td>1.23</td>
<td>1.82</td>
</tr>
<tr>
<td>Pre &amp; Post depression</td>
<td>1.16</td>
<td>0.90</td>
<td>1.49</td>
</tr>
<tr>
<td>No Depression</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Appalachian Status</strong></td>
<td></td>
<td></td>
<td>0.0102</td>
</tr>
<tr>
<td>Non-Appalachian</td>
<td>1.20</td>
<td>1.04</td>
<td>1.37</td>
</tr>
<tr>
<td>Appalachian</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Age at Diagnosis</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>50-65</td>
<td>1.15</td>
<td>0.88</td>
<td>1.50</td>
</tr>
<tr>
<td>65-74</td>
<td>1.37</td>
<td>1.03</td>
<td>1.82</td>
</tr>
<tr>
<td>75+</td>
<td>2.59</td>
<td>1.95</td>
<td>3.44</td>
</tr>
<tr>
<td>21-49</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Smoking Status</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Smoker</td>
<td>1.38</td>
<td>1.23</td>
<td>1.55</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.23</td>
<td>1.07</td>
<td>1.40</td>
</tr>
<tr>
<td>Non-smoker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Marital Status</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Never Married</td>
<td>1.57</td>
<td>1.29</td>
<td>1.91</td>
</tr>
<tr>
<td>Seperated/Divorced/Widowed</td>
<td>1.24</td>
<td>1.10</td>
<td>1.40</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.10</td>
<td>0.85</td>
<td>1.43</td>
</tr>
<tr>
<td>Married</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>High School or more</strong></td>
<td></td>
<td></td>
<td>0.0008</td>
</tr>
<tr>
<td>&lt;65%</td>
<td>1.38</td>
<td>1.15</td>
<td>1.65</td>
</tr>
<tr>
<td>65%–&lt;75%</td>
<td>1.30</td>
<td>1.12</td>
<td>1.51</td>
</tr>
<tr>
<td>75%–&lt;85%</td>
<td>1.33</td>
<td>1.14</td>
<td>1.54</td>
</tr>
<tr>
<td>Unknown</td>
<td>0.79</td>
<td>0.32</td>
<td>1.93</td>
</tr>
<tr>
<td>&gt;=85%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary payer</strong></td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>No insurance</td>
<td>4.53</td>
<td>1.42</td>
<td>14.49</td>
</tr>
<tr>
<td>Medicare</td>
<td>1.45</td>
<td>1.14</td>
<td>1.84</td>
</tr>
<tr>
<td>Medicaid/Other Public</td>
<td>1.82</td>
<td>1.37</td>
<td>2.42</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.81</td>
<td>1.35</td>
<td>2.43</td>
</tr>
<tr>
<td>Private insurance</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tables 4. Adjusted Cox hazard regression to identify the association between depression and survival (Cont.)

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charlson Score</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>1</td>
<td>1.27</td>
<td>1.11</td>
<td>1.44</td>
</tr>
<tr>
<td>&gt;=2</td>
<td>1.90</td>
<td>1.68</td>
<td>2.16</td>
</tr>
<tr>
<td>Missing</td>
<td>1.67</td>
<td>1.33</td>
<td>2.10</td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Stage II</td>
<td>1.86</td>
<td>1.61</td>
<td>2.15</td>
</tr>
<tr>
<td>Stage III</td>
<td>3.24</td>
<td>2.77</td>
<td>3.80</td>
</tr>
<tr>
<td>Stage IV</td>
<td>14.62</td>
<td>12.35</td>
<td>17.30</td>
</tr>
<tr>
<td>Unknown</td>
<td>5.16</td>
<td>3.80</td>
<td>7.01</td>
</tr>
<tr>
<td>Stage I Ref</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hormone Receptor</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Negative</td>
<td>1.45</td>
<td>1.27</td>
<td>1.66</td>
</tr>
<tr>
<td>Unknown</td>
<td>2.17</td>
<td>1.71</td>
<td>2.74</td>
</tr>
<tr>
<td>Positive Ref</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>1.41</td>
<td>1.19</td>
<td>1.67</td>
</tr>
<tr>
<td>Poorly/Undifferentiate</td>
<td>1.70</td>
<td>1.42</td>
<td>2.04</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.77</td>
<td>1.44</td>
<td>2.17</td>
</tr>
<tr>
<td>Well</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard Cancer Treatment</td>
<td></td>
<td></td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>No</td>
<td>2.20</td>
<td>1.95</td>
<td>2.49</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.08</td>
<td>0.78</td>
<td>1.47</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
RESULTS

Among the 6054 patients, 5212(86.1%) patients were not diagnosed with depression in both time periods, and 221(3.7%) patients had a depression diagnosis only within one year before the cancer diagnosis; meanwhile, 375(6.2%) patients had new recordings of depression after cancer diagnosis, and 246(4.1%) women both had depression diagnosis before and after cancer diagnosis. Table 1 presents the comparison of demographic characters and clinical information among the four groups. Compared with women who have not been diagnosed with depression, breast cancer patients who were identified as with depression during the baseline and follow-up period were statistically significantly more likely to be smokers, younger, from Medicare/other public insurance, not in a state of marriage, and with more comorbid diseases. Though Appalachian showed a slightly larger percentage of being diagnosed with depression, the increase was not statistically significant (p-value=0.99).

Table 2 displays the results of multivariable logistic regression. In the multivariable logistic regression analysis examining the influence of depression and Appalachian status on receiving nonguideline cancer treatment, 495 patients with unknown treatment information were excluded, and which resulted in 5559 eligible subjects in this analysis. 1770(31.8%) patients were defined as not receiving guideline treatment. After adjusting other variables that might impact the decision of treatment, no statistically significant association was found between depression and receiving nonguideline treatment (p-value=0.282), and patients only had pre-diagnostic depression showed an increased but nonsignificant odds ratio (OR, 1.38; 95% CI, 0.99-1.92) in receiving nonguideline treatment compared to patients without depression. Patients from Appalachian regions showed an increased association with receiving nonguideline treatment (OR, 1.23; 95% CI, 1.02-1.48).

Survival curves obtained from the Kaplan–Meier method (Figure 1) shows that patients diagnosed with depression only within one year before cancer diagnosis had the worst survival (more explanation needed?) Table 3 shows the results from the Cox regression analysis, the adjusted effect of depression on survival among breast cancer patients were shown. The association between depression and mortality was statistically significant (p-value<.001). Patients with new recordings of depression after the cancer diagnosis had a significant risk for death (HR, 1.50; 95% CI, 1.23-1.82). However, increased but nonsignificant risks for death were shown in patients diagnosed with depression only within one year before cancer diagnosis (HR, 1.23; 95% CI, 0.97-1.56) and patients had depression diagnosis in both periods (HR, 1.16; 95% CI, 0.90-1.49). Results also illustrated that patients received nonguideline cancer treatment showed a significantly higher adjusted hazard ratio (HR, 2.20; 95% CI, 1.95-2.49) than those received guideline treatment.
LESSONS LEARNED

• Finish early: This allows ideas and designs to stew. Finishing earlier provides more time to explore details and revise potential errors. Though there's some saying about the power of last-minute adrenalin-panic for increasing productivity, it's much less stressed when projects were planned and conducted ahead.

• Talk about the project. It's important to communicate with others by expressing my own project. In this process, I realized what I knew and didn't know about in this project, then I would search for relative information to learn those points I was not quite understand, and information I was missing helped me stay on track and discover new paths for research. Meanwhile, others may provide precious advice regarding this project.

• Summarize and create a list of resources. At the beginning, I found myself going back again and again to read related papers and study their methods and results, which was time-consuming to search and find those papers. Then, I decided to summarize those papers briefly and put the summary in one single word document. Whenever I needed to get basic information from those papers, I simply used that file to guide me.

• After half of the basic research is done, look for a really good summary of the field to reorient yourself. More broadly, make sure to take a breath and get perspective on your project and goals.

• Most Importantly:
  It is ok to say “I don’t know and I am having some troubles”. There were times I was having a hard time coding or understanding, but I was afraid to express that and only spent time worrying, which resulted in delays of some tasks. Then I learned the important lesson of admitting “I don’t know and I may not on the right track”, which actually reflects the sense of responsibility as a member of a team—we should keep on communicating the process of projects and letting others know whether we fully understand what we are doing.
Influence of depression on treatment and survival: a population-based study in patients with breast cancer in Kentucky

Abstract

BACKGROUND

Few prior studies have explored the impact of the combination of depression in two periods (before and after the cancer diagnosis) on guideline cancer treatment and survival among breast cancer survivors. With large area defined as Appalachian regions in Kentucky, the present study also aimed to find the disparity between Appalachian and non-Appalachian regarding developing depression and receiving standard cancer treatment.

METHODS

Kentucky Cancer Registry (KCR) data linked with Medicare, Medicaid, and private insurance claims data was used in this study. 6054 patients with primary invasive breast cancer aged 20 or older at the time of cancer diagnosis from 2007 to 2011 were included. 12 months before and 13 months from cancer diagnosis were two time periods to searching for depression diagnosis in claims data. Multivariate logistic regression and multivariate Cox regression were separately performed to assess the effect of the combination of depression at two periods on patients’ receiving of guideline cancer treatment and overall survival.

RESULTS

There was no statistically significant association between depression and receiving nonguideline treatment ($p=0.2815$). Patients reside in the Appalachian area had a significantly higher risk of receiving nonguideline cancer treatment (odds ratio, 1.23; 95% CI, 1.02-1.48). Significant associations between depression and survival were found in patients with newly diagnosed depression diagnosis after cancer diagnosis (hazard ratio, 1.50; 95% CI, 1.23-1.82). Increased but nonsignificant risks for death were also identified in patients with pre-diagnostic depression only or patients with a depression diagnosis in both periods.

CONCLUSIONS

Depression did not contribute to receiving nonguideline treatment among breast cancer patients, and Appalachian patients were statistically significantly more likely to receive nonguideline treatment. Patients with newly diagnosed depression after the cancer diagnosis had a significantly increased risk of death.

KEYWORDS: depression, breast cancer, guideline cancer treatment, survival, Appalachian
INTRODUCTION

Breast cancer is the most commonly diagnosed cancer except for skin cancer, and it also is the second leading cause of cancer death in women. Currently, more than three million women are living with breast cancer in the United States\(^1\). Previous studies have illustrated breast cancer survival is influenced by factors including age, ethnicity, comorbidity, smoking status, socioeconomic factors, stage of cancer at diagnosis, and cancer treatment\(^2\)-\(^9\).

Depression is a noticeably common mental health outcome among breast cancer survivors, and its hypothesized association with adverse survival in breast cancer patients has been of interest in the past decade. Studies estimated that about 10% to 25% of breast cancer patients experience depression, which is higher compared with matched control group\(^10,11\); however, associations between depression and survival found by prior studies remained inconsistent. For most studies which determined depression status in breast cancer patients depended on self-report questionnaires, the association between depression and survival has not been recognized\(^12\)-\(^16\). Though some of these studies have illustrated the relationship between depression and survival\(^17\)-\(^19\), the relatively brief depression measurement using questionnaires is limited compared to depression diagnosis based on systematic clinical consultations. By capturing depression based on clinical diagnosis, two large retrospective studies demonstrated breast cancer patients with depression had a higher likelihood of death\(^20,21\); however, both studies did not include covariates like lifestyle, socioeconomic factors, hormone receptor status. Several of these variables could predict higher mortality in breast cancer patients\(^8,22-24\).

From a clinical perspective, we are also curious about whether patients with a depression diagnosis are a vulnerable patient group that received nonguideline cancer treatment, which also may lead to worse survival in breast cancer survivors. Two previous studies have reported depression as a negative predictor of receiving guideline cancer care\(^25,26\). However, one study only included elder patients who were 67 years old or older at the time of breast cancer diagnosis\(^25\), and another study conducted in Denmark only assessed the relationship between depression and adjuvant systemic therapy\(^26\).

No prior studies have investigated the influence of combinations of depression in two time periods (before and after cancer diagnosis) on the survival and guideline treatments, which distinguishes breast cancer patients who were not depressed, who were diagnosed with depression only before cancer, who were diagnosed with depression only after cancer diagnosis, and who were depressed before and after cancer diagnosis, and this allows more detailed study on the influence of depression. Previous studies have investigated the effect of pre/post-diagnostic depression on the survival in breast cancer patients\(^20,21\). One of them explored the influence depending on the onset of depression separately\(^20\), and another only
compared the influence of pre-diagnostic depression and new recordings of depression after cancer diagnosis.

The Kentucky Cancer Registry (KCR) data linked with Medicare, Medicaid, and private insurance administrative claims data were utilized in this study. Importantly, this study included records from privately insured patients, who continue to comprise the largest segment of US healthcare users, and few population-based studies in this field had been linked to private insurance claims data. Patients resided in Kentucky were obtained from this data. Kentucky has the highest cancer incidence and mortality rates in the U.S. There’re 54 counties defined as Appalachian in Kentucky, and many of these counties are identified as economically depressed, the most rural, and underserved communities in the U.S. Cancer death rates in rural Appalachian counties in Kentucky were nearly 36% higher than in non-Appalachian urban areas nationwide. Of note, breast cancers were found at more advanced stages in women living in Appalachian states, and the 3- to 5-year survival rates for all cancers were lower compared with cases from urban non-Appalachian communities. Therefore, except for the primary objectives of examining the influence of depression on standard treatment and survival in breast cancer patients, we also conducted the study with a secondary focus on the Appalachian regions to explore whether there’re disparities between Appalachian areas and non-Appalachian areas. In conclusion, we hypothesized that: (1) depression is associated with receiving nonguideline cancer treatment in breast cancer patients; (2) depression predicts worse survival in breast cancer survivors; (3) Appalachian patients are more likely to experience depression and receive nonguideline cancer treatment.

MATERIALS AND METHODS

Data source

Incident breast cancer cases were obtained from the Kentucky Cancer Registry (KCR), which is a member of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. The KCR data provide information about demographics, tumor characteristics, initial treatment, and survival of cancer patients. In this study, KCR data have been linked to Medicare, Medicaid, and private insurance administrative databases. These administrative databases consist of beneficiaries’ covered health care services, from the time of insurance eligibility until dropout or death, which includes inpatient claims, outpatient claims, and prescription drug usage. In addition, to obtain the census tract socioeconomic information, KCR data were linked with the American Community Survey (ACS) 2007-2011 census tract and zip code files by census tract codes. These files were used to derive education level and below poverty percentage.
A total of 12,792 patients with invasive primary breast cancer and aged 20 or older at the time of cancer diagnosis from 2007 to 2011 were collected from the KCR linked data. Patients diagnosed through autopsy or death certification have already been excluded from this cohort. Subjects who were not continuously enrolled in claims data 12 months before and 13 months from cancer diagnosis were then excluded because of possible incomplete claims for medical services, which yielded 6,054 eligible subjects in the study.

Depressions

Depression diagnosis was determined by an algorithm developed by the Centers for Medicare and Medicaid Services (CMS) Chronic Conditions Data Warehouse. Individuals were identified with a depression diagnosis if the following International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes shown in inpatient or outpatient visit in claims data, including: 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 298.0, 300.4, 309.0, 309.1, or 311.0.

A baseline period and a follow-up period were used in this cohort study to capture depression diagnosis, and the date of cancer diagnosis was designated as the index date. The period of 12 months prior the cancer diagnosis was defined as the baseline period, and the period included the month of cancer diagnosis and 12 months after the cancer diagnosis was designate as the follow-up period. Cancer patients were defined as with pre-diagnosis depression if they were with at least one depression diagnosis during the baseline period. Post-diagnosis depression was defined as any depression diagnosis recorded during the follow-up period. According to the depression diagnosis in baseline and follow-up periods, patients were classified as the following four groups: 1. No depression. Patients with no depression diagnosis in both time periods; 2. Pre-diagnostic depression only. Patients only had depression diagnosis in the baseline period and no depression diagnosis in the follow-up period; 3. Post-diagnostic depression only. Patients only had depression diagnosis after cancer diagnosis; 4. Depression in both periods. Patients had depression diagnosis in both baseline and follow-up periods.

Cancer treatment

Standard treatment for breast cancer was based on claims data as therapy received during the follow-up period. Guideline treatment was defined as follows: first all, if patients have hormone receptor-positive (estrogen receptor (ER)-positive or progesterone receptor (PR)-positive) breast cancer, hormone therapy is included as standard care for all stages. Apart from this, for Stage 1 and 2 cancer, modified radical mastectomy or lumpectomy with adjuvant irradiation is required. Meanwhile, if the cancer is not hormone receptor-positive, chemotherapy is defined as standard care. For stages 3, either begin with neoadjuvant therapy or surgery are appropriate, and followed irradiation is required. For stage 4, hormone therapies are used for as long as possible before chemotherapy is introduced if the cancer is hormone receptor-positive. As for patients with hormone-negative cancer, chemotherapy is the primary
treatment. These definitions were based on published practice recommendations\textsuperscript{30}. According to these definitions, a new indicator variable was created to imply whether appropriate initial therapy was received for each subject. Because of the incompleteness of immunity therapy for human epidermal growth factor receptor 2(HER2) in KCR linked data, receiving necessary immunity therapy was not defined as a criterion when identifying guideline treatment.

Covariates

Demographic variables included in the analysis such as age at cancer diagnosis, smoking status, race, Appalachian status, marital status, and primary payer were obtained from the KCR data, and they were used to categorize subjects. Age at the cancer diagnosis will be classified into categorical variables. The ACS 2007-2011 census tract and zip code files provided information on the census tract education level and below poverty percentage after being linked with KCR data. Survival after cancer diagnosis in the study population was obtained from KCR. Overall mortality (death from any causes) was of interest in this study, and the censored date is the most recent available date that captures the death information. The Charlson Comorbidity Index developed for claims data was utilized to measure comorbidity. Concerning clinical variables, the stage at cancer diagnosis, grade, tumor size, and estrogen/progesterone receptors status were derived from the KCR data. Cancer treatment information including chemotherapy, radiation therapy, hormone therapy, and surgery was obtained from the claims data.

Statistical Analysis

Patients were classified into four groups based on depression in the baseline and follow-up periods, and the comparison of the characteristics and clinical information among these groups will be conducted. Proportions were used to describe these categorical variables. A chi-square test was used to analyze categorical variables. Multivariable logistic regression will then be performed to examine the adjusted association between depression and receiving nonguideline cancer treatment, as well as the adjusted association between Appalachian status and receiving nonguideline treatment, controlling for age, race, marital status, education level, poverty level, primary payer, stage, comorbidity, hormone receptor status. Patients with unknown treatment information were excluded from this analysis. Survival rates were first illustrated using the Kaplan–Meier method stratified by depression. Multivariate Cox proportional hazards regression was then used to estimate adjusted HR. The Cox regression will be conducted by adjusting age at diagnosis, smoking status, race, marital status, Appalachian status, primary payer, comorbidity, stage, grade, hormone receptor status, her2-neu status, and appropriate cancer treatment. Of note, instead of adjusting treatment types such as surgery, chemotherapy, and radiation therapy, whether receiving guideline cancer care was controlled in this survival analysis. Statistical significances were determined as two-sided P values < .05.

RESULTS
Among the 6054 patients, 5212 (86.1%) patients were not diagnosed with depression in both periods, and 221 (3.7%) patients had a depression diagnosis only within one year before the cancer diagnosis; meanwhile, 375 (6.2%) patients had new recordings of depression after cancer diagnosis, and 246 (4.1%) women both had depression diagnosis before and after cancer diagnosis. Table 1 presents the comparison of demographic characters and clinical information among the four groups. Compared with women who have not been diagnosed with depression, breast cancer patients who were identified as with depression during the baseline and follow-up period were statistically significantly more likely to be smokers, younger, from Medicare/other public insurance, not in a state of marriage, and with more comorbid diseases. Though Appalachian showed a slightly larger percentage of being diagnosed with depression, the increase was not statistically significant (p-value=0.99).

Table 2 displays the results of multivariable logistic regression. In the multivariable logistic regression analysis examining the influence of depression and Appalachian status on receiving nonguideline cancer treatment, 495 patients with unknown treatment information were excluded, and which resulted in 5559 eligible subjects in this analysis. 1770 (31.8%) patients were defined as not receiving guideline treatment. After adjusting other variables that might impact the decision of treatment, no statistically significant association was found between depression and receiving nonguideline treatment (p-value=0.282), and patients only had pre-diagnostic depression showed an increased but nonsignificant odds ratio (OR, 1.38; 95% CI, 0.99-1.92) in receiving nonguideline treatment compared to patients without depression. Patients from Appalachian regions showed an increased association with receiving nonguideline treatment (OR, 1.23; 95% CI, 1.02-1.48).

Survival curves obtained from the Kaplan–Meier method (Figure 1) shows that patients diagnosed with depression only within one year before cancer diagnosis had the worst survival. Table 3 shows the results from the Cox regression analysis, the adjusted effect of depression on survival among breast cancer patients were shown. The association between depression and mortality was statistically significant (p-value<.001). Patients with new recordings of depression after the cancer diagnosis had a significantly higher risk of death (HR, 1.50; 95% CI, 1.23-1.82). However, increased but nonsignificant risks for death were shown in patients diagnosed with depression only within one year before cancer diagnosis (HR, 1.23; 95% CI, 0.97-1.56) and patients had depression diagnosis in both periods (HR, 1.16; 95% CI, 0.90-1.49). Results also illustrated that patients received nonguideline cancer treatment showed a significantly higher adjusted hazard ratio (HR, 2.20; 95% CI, 1.95-2.49) than those received guideline treatment.

DISCUSSION

In this population-based cohort study in Kentucky, the results can be summarized as follows. We did not find the support for the hypothesis that a diagnosis of depression was associated...
with less likelihood of receiving guideline cancer treatment. Newly-diagnosed depression after
the cancer diagnosis was identified as a negative predictor of survival for breast cancer
patients. Meanwhile, increased but nonsignificant risks for death were shown in patients
diagnosed with depression only within one year before cancer diagnosis and patients had
depression diagnosis in both periods. As for the discrepancy between Appalachian and non-
Appalachian, Appalachian showed increased risks of nonguideline cancer treatment, neither of
the two increased risks was statistically significant.

The finding that patients with depression are not a vulnerable group of not receiving guideline
cancer treatment was not in accordance with previously studies\textsuperscript{25,26}. Compared to Goodwin’s
focus on a population of patients aged 67 or older\textsuperscript{25}, our results apply to a broader age
range(\textgeq 20 years of age). Meanwhile, using diagnostic of depression in this study rather usage
of antidepressants\textsuperscript{26} as a predictor is more accurate when examining the association between
depression and the outcome because anxiety and pain relief constitutes more than one-quarter
use of prescribed antidepressants\textsuperscript{31,32}. Though, we assumed that patients with depression
might show less motivation and a decreased level of self-management, which may lead to a
poorer commitment to receiving guideline treatment. Our findings indicated that the adjusted
likelihood of receiving nonguideline treatment in patients with depression was not significantly
higher than in patients without depression. The discrepancy between receiving guideline
treatment or not was more determined by socioeconomic factors and clinical variables such as
stage, comorbidity, and hormone receptor status.

A five-year observational cohort study has reported that almost half of the early breast cancer
patients expressed depression, anxiety, or both in the first year after cancer diagnosis, and the
prevalence dramatically dropped to 25% in the second year\textsuperscript{33}. Therefore, the follow-up period
of capturing post-diagnosis depression seems feasible in this study. As for pre-diagnosis
depression, two other population-based studies of breast cancer mortality have demonstrated
significantly worse overall survival in patients with pre-diagnosis depression\textsuperscript{20,21}. However, this
association was not found in this study; patients who were diagnosed with depression only
before cancer diagnosis or had depression both before and after cancer diagnosis did not show
significantly worse overall survival compared to patients without depression. This might be
explained by the shorter baseline time to capture prior diagnosis of depression in our study
compared to two others. One study examined the population of southeast England identified
pre-diagnosis depression as any diagnosis of depression three years before cancer breast
diagnosis\textsuperscript{21}. Another study conducted in Denmark even defined pre-diagnosis depression as any
first-ever psychiatric admission with depressive disorders at age 15 years or older before the
date of first breast cancer diagnosis\textsuperscript{20}. Thus, compared to these two studies, fewer individuals
would be determined as with pre-diagnostic depression, and this might result in the different
results. Importantly, after removing the variable- “appropriate cancer treatment” from the
multivariate Cox regression model, patients with depression diagnosis only before cancer
diagnosis showed a significantly worse overall survival (HR=1.41, 95% CI, 1.21-1.74). It implied
that patients in this group are more likely to receive nonguideline treatment, which resulted in worse survival; however, this relationship was adjusted when including the guideline treatment variable in the Multivariate Cox model. Thus, we found a nonsignificant association between pre-diagnostic only and mortality.

Patients with newly diagnosed depression were found significantly more likely to have worse overall survivals. However, there’s no significant difference between patients without depression and patients with depression both before and after a cancer diagnosis. This could be interpreted that persistent depression diagnosis represents patients with depression were recognized and managed. Thus, earlier detection and well-management of depression may have had a more positive influence on health behaviors and compliance with cancer treatment. Davis’s report also reported a similar conclusion that patients with metastatic breast cancer with decreased depressive symptoms in the first year were more likely to have a longer subsequent survival; thus, we may infer that effective treatment of depression improves survival in patients with breast cancer, though further research is needed to confirm this assumption.

A study has shown that women with depression from poverty regions than all breast cancer had a higher risk of experiencing depression; besides, adjuvant endocrine therapy adherence and persistence was lower in Appalachia regions compared to national level. Therefore, we hypothesized that breast cancer patients residing in Appalachian areas would present higher risks of experiencing depression and receiving nonguideline breast cancer treatment. However, no significant difference of developing depression between Appalachian and non-Appalachian was found in this study. It was likely was due to the lower presence of community mental health clinics, and the larger shortage of mental health-care in Appalachian areas, breast cancer patients living in these areas had less access to psychiatry visits and thus were less likely to be diagnosed with depression.

The main advantages of the present study included larger sample size than most of the studies in this field, same classification system, the completeness and sound quality of the KCR registry data and administrative claims data, and the relatively comprehensive controlling for survival-related prognostic covariates. Especially for variables like smoking status, ER status, PR status, and HER2 status, though they are highly associated with breast cancer survival, they were seldom involved in previous studies. Of note, introducing the combination of depression in two periods (before and after the cancer diagnosis) to classify patients could distinguish the effect of the cancer diagnosis on developing depression, which has been seldom used in this field. As for the limitations of this study, first of all, the exclusion of patients without continuous enrollment in claims data may result in the miss of valuable information. It is more often that women with a lower socioeconomic status were more likely to drop from insurance than the general female population, and low socioeconomic has consistently shown a relationship with significantly worse survival in breast cancer patients.
In conclusion, among women with primary invasive breast cancer in Kentucky, we found that patients from Appalachian had a statistically significantly higher risk for not receiving guideline cancer treatment, and patients only with a pre-diagnostic showed an increase but nonsignificant increased risk of receiving nonguideline treatment. The nonguideline cancer treatment would result in worse survival among these breast cancer patients, which indicates that improvement of breast cancer guideline treatment in this group of patients may increase the post-diagnostic survival in these groups. Besides, newly diagnosed depression after a cancer diagnosis had a significant association with adverse overall mortality. As a result, introducing social support, psychological interventions, or depression screening for breast cancer patients after cancer diagnosis especially within one year after cancer diagnosis were recommended. The target population is patients who are with lower socioeconomic status, living alone, in younger age groups, benefiting from Medicaid or other public insurance, and presenting more comorbidities. As for the different likelihood of receiving nonguideline cancer treatment between Appalachian and non-Appalachian breast cancer patients, improvement of medical services should be promoted for Appalachian patients, which will lead to better survival in this underserved group.

References


